8-K: Kewaunee Scientific Reports FY25 Growth, NuAire Integration

Kewaunee Scientific Corporation announced its fiscal year 2025 results, highlighting significant sales growth and the strategic acquisition of NuAire, Inc., despite a decrease in reported net earnings.

Summary

• Fiscal Year 2025 net sales increased by 18.0% to $240.5 million, up from $203.8 million in the prior year.
• Reported net earnings for FY2025 were $11.4 million, a decrease from $18.8 million in the prior year.
• Reported diluted earnings per share were $3.83, down from $6.38 in the prior fiscal year.
• Adjusted net earnings for FY2025 were $16.0 million, an increase from $12.3 million in the prior year, after accounting for acquisition and pension-related costs.
• Adjusted diluted earnings per share were $5.37, up from $4.19 in the prior year.
• EBITDA for FY2025 was $21.6 million, compared to $16.6 million for the prior fiscal year.
• Adjusted EBITDA for FY2025 was $26.5 million, an increase from $20.7 million in the prior year.
• The company completed the acquisition of NuAire, Inc. on November 1, 2024, expanding its product offerings in biosafety and containment equipment.
• Order backlog stood at $214.6 million on April 30, 2025, an increase from $155.6 million on April 30, 2024, but a slight decrease from $221.6 million on January 31, 2025.

Sentiment

Score: 7

Explanation: The company reported strong sales growth and positive adjusted earnings, indicating healthy underlying performance despite one-time acquisition costs. The strategic acquisition of NuAire and a robust backlog position the company well for future growth in a favorable industry. However, the reported decline in GAAP earnings and EPS due to acquisition-related expenses introduces some short-term noise.

Positives

• Net sales increased by 18.0% to $240.5 million in fiscal year 2025.
• Gross profit rose to $68.9 million in FY2025 from $52.1 million in FY2024.
• Adjusted operating profit increased to $23.5 million in FY2025 from $18.3 million in FY2024.
• Adjusted net earnings increased to $16.0 million in FY2025 from $12.3 million in FY2024.
• Adjusted diluted earnings per share increased to $5.37 in FY2025 from $4.19 in FY2024.
• Adjusted EBITDA increased to $26.5 million in FY2025 from $20.7 million in FY2024.
• Successful acquisition of NuAire, Inc. on November 1, 2024, significantly expanding the product portfolio in specialized laboratory equipment.
• Robust and healthy order backlog of $214.6 million as of April 30, 2025, indicating strong future demand.
• Strategic expansion into high-demand areas like large-molecule research, requiring specialized equipment.

Negatives

• Reported operating earnings decreased to $17.8 million in FY2025 from $18.3 million in FY2024.
• Reported net earnings decreased to $11.4 million in FY2025 from $18.8 million in FY2024.
• Reported diluted earnings per share decreased to $3.83 in FY2025 from $6.38 in FY2024.
• Incurred $6.0 million in professional fees and other costs related to the NuAire acquisition, impacting pre-tax earnings.
• Fiscal year results were impacted by purchase accounting related to the write-up of various assets on NuAire's books.
• Order backlog saw a slight decrease from $221.6 million on January 31, 2025, to $214.6 million on April 30, 2025.

Risks

• Competitive and general economic conditions, including disruptions from government mandates, both domestically and internationally, as well as supplier constraints and other supply disruptions.
• Changes in customer demands.
• Technological changes in operations or in the industry.
• Dependence on customers' required delivery schedules.
• Risks related to fluctuations in operating results from quarter to quarter.
• Risks related to international operations, including foreign currency fluctuations.
• Changes in the legal and regulatory environment.
• Changes in raw materials and commodity costs.
• Risks associated with the ability to identify and complete strategic acquisitions or to successfully integrate any businesses that may be acquired.
• Acts of terrorism, war, governmental action, natural disasters, and other Force Majeure events.
• Actual results, performance, or achievements will likely differ from the anticipated results, performance or achievements that are expressed or implied by forward-looking statements, and such difference might be significant and harmful to stockholders' interest.

Future Outlook

The company is committed to sustainable, continuous growth through both organic development and thoughtful acquisitions, actively pursuing strategic acquisitions that complement existing businesses, enhance product offerings, expand geographic reach, and strengthen distribution channels. Management anticipates a rise in demand for more specialized equipment, such as isolators, biosafety cabinets, and advanced laminar airflow systems, as research shifts from small to large-molecule research.

Management Comments

• "Fiscal year 2025 was marked by exceptional performance from our Kewaunee team. The Company delivered excellent financial results and closed the year with a robust and healthy backlog."
• "This move was guided by a clear strategic intent: To bring together two market leaders with complementary strengths, shared values, and a common vision for the future of laboratory innovation."
• "As the focus of research shifts from small to large-molecule research, we anticipate a rise in demand for more specialized equipment, such as isolators, biosafety cabinets (BSCs), and advanced laminar airflow systems, in which NuAire is a recognized leader."
• "At Kewaunee, we believe in empowering the scientific community with spaces that inspire, innovate, and integrate."
• "Our customers operate within multiple end-use markets, which require high-quality laboratory furniture and technical products to furnish their environments. These markets tend to enjoy a durable, long-term growth trend with consistent funding from private and public parties."
• "We believe that our industry presents meaningful opportunities for consolidation. As such, we will actively pursue strategic acquisitions that complement our existing businesses, enhancing our product offerings, expanding our geographic reach, and strengthening our distribution channels."
• "Kewaunee provides a unique and stable platform for companies seeking a thoughtful succession or exit strategy."
• "Kewaunee's future is bright, and I am excited to continue building on our momentum in fiscal 2026."

Industry Context

The company operates in the laboratory furniture and technical products industry, serving life sciences, education, healthcare, industrial, petrochemical, and government research markets. These markets are characterized by durable, long-term growth trends and consistent funding from both private and public sources. The shift towards large-molecule research is driving increased demand for specialized equipment like biosafety cabinets and laminar airflow systems, a trend Kewaunee is capitalizing on through its acquisition of NuAire, a leader in these products. The industry also presents opportunities for consolidation, which Kewaunee intends to pursue through strategic acquisitions.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to global benchmarks. It generally states that its end markets enjoy durable, long-term growth trends with consistent funding, implying a favorable industry position without specific comparative data.

Stakeholder Impact

• Shareholders: Potential for long-term value creation through strategic acquisitions and market expansion, but short-term reported earnings were impacted by acquisition costs.
• Employees (Associates): Company is committed to investing in Associates with meaningful well-being, educational, and rewards opportunities, fostering a culture of safety, quality, and innovation.
• Customers: Broader, more powerful portfolio of solutions with NuAire acquisition, better equipped to advance safety, performance, and scientific discovery in laboratory environments.
• Channel Partners: Deepened relationships and expanded capabilities and reach, fueling continued success.
• Business Owners (potential acquisition targets): Kewaunee offers a stable platform for succession or exit strategies, committed to preserving legacy, culture, people, and customer relationships.

Next Steps

• Continue sustainable, continuous growth through organic development and thoughtful acquisitions.
• Actively pursue strategic acquisitions that complement existing businesses, enhancing product offerings, expanding geographic reach, and strengthening distribution channels.
• Release earnings for the first quarter of fiscal year 2026 after the close of business on September 10, 2025.

Key Dates

Recommendation

While Kewaunee Scientific demonstrated strong top-line growth and positive adjusted financial performance, the reported GAAP net earnings and diluted EPS saw a significant decline due to one-time acquisition and purchase accounting costs related to the NuAire acquisition. The strategic rationale for the NuAire acquisition is sound, expanding the company's market presence in high-growth areas. The robust backlog also indicates healthy future demand. However, the short-term impact on reported profitability and the ongoing integration efforts warrant a cautious 'hold' stance until the benefits of the acquisition are more clearly reflected in GAAP results and integration risks are fully mitigated. Long-term prospects appear favorable, but near-term clarity is needed.

Keywords

Kewaunee Scientific, KEQU, NuAire Acquisition, Laboratory Equipment, Biosafety Cabinets, Financial Results, FY2025 Earnings, Investor Presentation, Life Sciences, Healthcare Research, Lab Furniture, Biomedical Research, Corporate Strategy, Backlog